Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).
Following the completion of the build and optimization of a tailored AI model in June 2022, the OneThree team, using its clinically validated AI platform, have identified novel drug targets using Poolbeg Pharma’s RSV human challenge trial data.
The identification of these novel drug targets allows the final stage of the program to start, which will involve the identification of small molecule inhibitors to effectively treat RSV infections. The team said this includes a range of targets for which there are known drugs with existing phase I safety and tolerability data.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
